BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company specializing in novel antibacterials for life-threatening infections caused by multi-drug resistant (MDR) bacteria, today announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference. The event, scheduled for September 14-16, 2026 in New York City, will feature a corporate overview presented by BioVersys' Chief Financial Officer, Hernan Levett, on September 16, 2026 from 12:30 PM to 1:00 PM ET at the Kennedy II room of the Lotte New York Palace. Additionally, Chief Executive Officer Dr. Marc Gitzinger will deliver an on-demand presentation available via the conference platform starting September 11, 2026 at 7:00 AM ET, with a replay accessible for 90 days.
This presentation comes at a pivotal time for BioVersys, which is advancing a robust pipeline addressing the urgent global health threat of antimicrobial resistance. The company's most advanced programs target nosocomial infections caused by Acinetobacter baumannii (BV100, currently in Phase 3) and tuberculosis (alpibectir, in Phase 2, in collaboration with GlaxoSmithKline (GSK) and a consortium led by the University of Lille, France). These efforts underscore BioVersys' commitment to developing novel treatment options that overcome resistance mechanisms and address high unmet medical needs.
The significance of this conference participation lies in the opportunity for BioVersys to communicate its strategic vision and recent progress to the investment community. With the rise of MDR bacteria posing a growing public health crisis, the company's work on innovative solutions positions it at the forefront of the antibacterial development landscape. The presentation will likely highlight the clinical advancements of its lead candidates and the potential market opportunities, providing investors with insights into the company's growth trajectory.
BioVersys leverages its proprietary TRIC and Ansamycin Chemistry platforms to design candidates that not only overcome resistance but also block virulence production and directly affect bacterial pathogenesis. This dual approach enables the company to explore treatments not only for acute infections but also for chronic inflammatory microbiome disorders exacerbated by bacteria. This broad applicability enhances the commercial potential of its pipeline.
The H.C. Wainwright conference serves as a key venue for biotech companies to engage with institutional investors, analysts, and potential partners. BioVersys' management, including CEO Dr. Marc Gitzinger and CFO Hernan Levett, will be available for one-on-one meetings during the event. Registered attendees can request meetings through their H.C. Wainwright representatives, facilitating direct dialogue about the company's milestones and future plans.
For those unable to attend in person, the on-demand presentation provides access to BioVersys' corporate update. The webcast will be accessible on the H.C. Wainwright platform and on the BioVersys website in the investor section. This accessibility ensures that a broader audience, including global investors and media, can stay informed about BioVersys' developments.
BioVersys is headquartered in Basel, Switzerland, a hub for biotechnology innovation. The company's focus on MDR infections is critical, as these pathogens are responsible for significant morbidity and mortality worldwide. By presenting at this prestigious conference, BioVersys aims to underscore its role in addressing this public health emergency while showcasing its scientific and clinical advancements to potential stakeholders.
As the conference approaches, BioVersys' participation signals its proactive communication strategy and its dedication to advancing its pipeline. The insights shared at the conference will likely provide a clearer picture of the company's path forward, including upcoming milestones and strategic partnerships. With a growing portfolio and a clear vision, BioVersys continues to make strides in the fight against antimicrobial resistance.
